Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510224 · ClinicalTrials.gov registry record · Phase 2
Sandostatin for Patients With Androgen Independent Prostate Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00510224 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 13 participants.
The verdict
NCT00510224, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is an open label, single center Phase II trial of Sandostatin LAR in patients with hormone refractory prostate cancer. Patients will receive Sandostatin LAR 30 mg intramuscularly every 28 days. Patients will be treated until the time of disease progression, unacceptable toxicity or withdrawal of consent. The study will require 27 evaluable patients.
Interventions
- DRUG Sandostatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510224
The ClinicalTrials.gov registry entry for NCT00510224 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sandostatin is the first listed.
NCT00510224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00510224 about?
NCT00510224 is a clinical study titled "Sandostatin for Patients With Androgen Independent Prostate Cancer". This is an open label, single center Phase II trial of Sandostatin LAR in patients with hormone refractory prostate cancer. Patients will receive Sandostatin LAR 30 mg intramuscularly every 28 days. Patients will be treated until the time of disease progression, unacceptable toxicity or withdrawal o...
What is the current status of trial NCT00510224?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2007-07. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00510224?
The interventions under investigation include: Sandostatin (DRUG).
Who is sponsoring clinical trial NCT00510224?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.